MIRA
INFORM REPORT
|
Report Date : |
01.11.2007 |
IDENTIFICATION
DETAILS
|
Name : |
HAN KOOK
CAPSULE INDUSTRY CO., LTD. |
|
|
|
|
Registered Office : |
13-164, Seongsu 1-ga 2-dong, Seongdong-gu, Seoul - 133-822 |
|
|
|
|
Country : |
Korea |
|
|
|
|
Date of Incorporation : |
06/04/1980 |
|
|
|
|
Legal Form : |
Company Limited by Shares |
|
|
|
|
Line of Business : |
Manufacture of Pharmaceutical Goods Other than Medicaments |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Basic
|
Company
Name |
HAN KOOK CAPSULE INDUSTRY CO., LTD. |
|
Registered Address/Factory |
13-164, Seongsu 1-ga 2-dong, Seongdong-gu,
Seoul, Korea |
|
Zip Code |
133-822 |
|
Tel |
+82-2-464-0621 |
|
Fax |
+82-2-464-9503 |
|
E-mail |
01196392192@naver.com;splinter@bcline.com |
|
Trading Address |
13-164, Seongsu 1-ga 2-dong, Seongdong-gu,
Seoul, Korea |
|
Tel |
+82-2-464-0621 |
|
Fax |
+82-2-464-9503 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Pharmaceutical Goods Other Than Medicaments |
|
Established (mm/dd/yyyy) |
06/04/1980 |
The Subject owns
the premises of registered HQ address/Factory.
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Capsule tubes or caps(24141709) |
|
Buy |
Gelatin(51131903) |
|
Buy |
Inks(12171703) |
CEO’s
|
Name |
Cho In-Sang |
|
Address |
577-36, Banpo-dong, Seocho-gu, Seoul, Korea |
|
Date of Birth |
05/04/1925 |
|
Title |
Chairman & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital |
650,000,000 KRW |
|
Employees |
88 |
|
Formation |
Co., Ltd by shares |
|
Bank Details |
Woori Bank-Sungsu Nam Branch |
|
Corporate Registered No. |
110111-0275994 |
|
Business Registered No. |
218-81-03378 |
|
Permit & Licenses |
Int’l Trade No.: 301280 |
|
Shareholder Position |
N/A |
|
Company History |
06/04/1980 Incorporated as the present
name |
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Day |
|
President & CEO |
Mr. |
Cho In-Sang |
Male |
Korean |
06/04/1980 |
|
Director |
Mr. |
Kim Kyung-Yong |
Male |
Korean |
03/14/1992 |
|
Director |
Mr. |
Cho Hang-Deok |
Male |
Korean |
04/27/1999 |
|
Director |
Mr. |
Cho Hang-Woo |
Male |
Korean |
03/14/2007 |
|
Auditor |
Mr. |
Kim Yeon-Han |
Male |
Korean |
03/14/2007 |
Financials
Unit: KRW
|
Year |
Sales |
Assets |
Net income |
|
2003 |
6,462,000,000 |
|
|
The latest financial is not available.
Financial Description
Unit: KRW
|
Authorized
Capital |
2,000,000,000 |
|
Paid-Up
Capital |
650,000,000 |
|
Total Issues Shares |
130,000 |
Products, Technologies, Services
Description
|
Main
Products & Services |
Empty Hard Gelatin Capsule |
Trade
Partners
|
Competitors |
SUHEUNG CAPSULE CO.,LTD(124311-0004252) |
Sales by
Region (Activity &
Markets)
The Subject exports to Canada, Chile and Europe.
Court
Action
|
Case No. |
Court |
Plaintiff(s)/
Creditor(s)/ Applicant(s) |
Defendant(s)/
Debtor(s)/ Respondent(s) |
Cause |
Amount (Million KRW) |
Status |
|
|
|
The Subject Company |
Korea Food & Drug Administration (KFDA) |
Cancellation on the imposed the order to
stop Manufacturing Operation |
|
Proceeding |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)